Menu
No results found.
AVTX
Avalo Therapeutics, Inc. – NASDAQ
Weekly Share Price & Valuation Overview
Market Overview
Open
9.6000
Close
9.0200
High
9.8000
Low
8.8030
Trend
0.30970
Avalo Therapeutics, Inc.
United States
• NASDAQ - Nasdaq
• AVTX
• Currency: USD
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Key strengths
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
Potential weaknesses
- Negative free cash flow — operations may rely on external financing.
Scale & Structure
Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares. Revenue estimated from Revenue/share × Shares.
- Market Cap Total equity value of the company (share price × shares outstanding).
- USD 118.63M
- Enterprise Value Operating value: market cap + total debt − cash.
- USD 6.05M
- Total Revenue (TTM) Estimated Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- USD 618.16K
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- USD -28.16M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- USD 0.05
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 6.54
- Shares Outstanding
- 13.15M
- Float Shares
- 6.95M
- Implied Shares Outstanding
- 13.15M
Profitability & Efficiency
TTM basis. “Reconciled” = numerator ÷ TTM revenue. EBITDA suppressed where implausible vs revenue. Margins reflect latest TTM calculations.
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-136.41%
- Gross Margin (TTM) Reconciled Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
-4,555.92%
- ROA Return on assets: net income ÷ total assets.
-
-32.01%
- ROE Return on equity: net income ÷ shareholder equity.
-
-90.24%
Growth
Growth rates are YoY unless labeled QoQ.
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
30.00%
Liquidity & Solvency
Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 12.23
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.65
- Total Cash Cash and equivalents.
- USD 113.26M
- Total Debt Short + long-term interest-bearing debt.
- USD 679.00K
- Net Debt Net Cash Total debt − cash (negative = net cash).
- USD -112.58M
Sharemaestro House View
Confidence: 1
Sharemaestro internal conviction (0–3, higher is better).
Risk: 1
Sharemaestro internal risk profile (0–3, higher is safer).
Operational: 1
Operational quality/consistency (0–3, higher is better).
Composite Score: 1
Overall internal composite (0–3, higher is better).
Suggested Allocation: 1.67%
Indicative portfolio weighting suggestion based on house view.
Structural Insights
(experimental)
Ownership & Liquidity
Free Float
Proportion of shares available for public trading.
52.9%
Insiders
Shares held by company insiders (officers, directors).
5.3%
Institutions
Shares held by institutions (funds, pensions).
64.1%
Capital Structure
Potential Dilution
Increase in share count if options/convertibles exercise.
None detected
Net Debt
Total debt − cash (negative = net cash).
USD -112.58M
-18212.5% of revenue
Net debt relative to revenue — debt load vs business scale.
Resilience Score
0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating.
100
Methodology Notes
- Total Revenue (TTM) estimated from Revenue per Share × Shares due to feed inconsistency.
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
As of: 2025-08-18 10:01
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.
AI generated insights not available yet. Sign in to generate the snapshot.